| MeSH term | MeSH ID | Detail |
|---|---|---|
| Asthenia | D001247 | 5 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Breast Neoplasms | D001943 | 24 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Lutz RJ and Whiteman KR | Antibody-maytansinoid conjugates for the treatment of myeloma. | 2009 Nov-Dec | MAbs | pmid:20068397 |
| Kovtun YV et al. | Antibody-maytansinoid conjugates designed to bypass multidrug resistance. | 2010 | Cancer Res. | pmid:20197459 |
| Yao Y et al. | Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography. | 2010 | J Sep Sci | pmid:20235129 |
| Mujagić H and Mujagić Z | Detection of pleiotropic drug resistance by the rapid immunofluorescence assay of drug effects on the cell skeleton. | 1991 | Oncology | pmid:2023698 |
| Wang HH et al. | Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors. | 2010 | J. Alzheimers Dis. | pmid:20413892 |
| Krop IE et al. | Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. | 2010 | J. Clin. Oncol. | pmid:20421541 |
| Jumbe NL et al. | Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. | 2010 | J Pharmacokinet Pharmacodyn | pmid:20424896 |
| Niculescu-Duvaz I | Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. | 2010 | Curr. Opin. Mol. Ther. | pmid:20521224 |
| Wei GZ et al. | A new antitumour ansamitocin from Actinosynnema pretiosum. | 2010 | Nat. Prod. Res. | pmid:20582809 |
| Monneret C | [Current impact of natural products in the discovery of anticancer drugs]. | 2010 | Ann Pharm Fr | pmid:20637355 |
| Wakankar AA et al. | Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. | 2010 | Bioconjug. Chem. | pmid:20698491 |
| Junttila TT et al. | Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. | 2011 | Breast Cancer Res. Treat. | pmid:20730488 |
| Junutula JR et al. | Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. | 2010 | Clin. Cancer Res. | pmid:20805300 |
| Higa GM et al. | Biological considerations and clinical applications of new HER2-targeted agents. | 2010 | Expert Rev Anticancer Ther | pmid:20836684 |
| Higa GM | The microtubule as a breast cancer target. | 2011 | Breast Cancer | pmid:20862571 |
| Lopus M et al. | Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. | 2010 | Mol. Cancer Ther. | pmid:20937594 |
| Oroudjev E et al. | Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. | 2010 | Mol. Cancer Ther. | pmid:20937595 |
| Lin J et al. | Enhanced production of ansamitocin P-3 by addition of isobutanol in fermentation of Actinosynnema pretiosum. | 2011 | Bioresour. Technol. | pmid:20980145 |
| Ikeyama S and Takeuchi M | Antitubulin activities of ansamitocins and maytansinoids. | 1981 | Biochem. Pharmacol. | pmid:21043240 |
| Harmrolfs K et al. | Cyclization of synthetic seco-proansamitocins to ansamitocin macrolactams by Actinosynnema pretiosum as biocatalyst. | 2010 | Chembiochem | pmid:21077088 |